- In October 2022, Eisaiannounced the final results from a real-world data (RWD) study assessing the clinical effectiveness of LENVIMA (lenvatinib) as a first-line therapy for patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC). Final analyses of the RWD study showed that 72.4% of patients treated with LENVIMA had a Best Overall Response (BOR) reported as a complete (26.9%) or partial (45.5%) response
- In May 2022, Ipsen received European Commission (EC) approval for the use of Cabometyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible for radioactive iodine who have progressed during or after prior systemic therapy. This is the first authorization of its sort in Europe for this uncommon illness, which currently has few treatment choices if patients progress after past systemic treatments
